Chemical Compound

Gefitinib

CAS Registry Number 184475-35-2
Back to search Request a Quote
Gefitinib chemical structure
Primary Record

Gefitinib

In stock
2,172 g
Purity
99.2 %
CAS
184475-35-2

Compound Identifiers & Properties

CAS
184475-35-2
PubChem CID
123631
SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Canonical SMILES
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1

Names & Synonyms

  • Gefitinib
  • Iressa
  • 184475-35-2
  • Irressat
  • gefitinibum
  • Tarceva
  • gefitinib (zd1839)
  • ZD1839
  • Gefitinib [USAN]
  • Gefitini
  • Gefitinib; Iressa
  • Gefitinib;
  • Irressat;
  • Iressa/Gefitinib
  • Gefitinib (GMP)
  • Gefitinib RS
  • Iressa(TM)
  • Gefitinib CRS
  • Gefitinib-d3
  • Iressa;
  • Gefitini; Iressa
  • Iressa (TN)
  • C22H24ClFN4O3
  • GefitinibZD1839
  • Gefitinib - Iressa
  • ZD-1839
  • IRRESSA
  • ZD 1839
  • Gefitinib (Standard)
  • Iressa (AstraZeneca)
  • nchembio866-comp14
  • Iressa-1839
  • Kinome_3321
  • Kinome_3322
  • CHEMBL939
  • GEFITINIB [INN]
  • GEFITINIB [JAN]
  • RefChem:58462
  • GEFITINIB [MI]
  • CCRIS 9011
  • GEFITINIB [VANDF]
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
  • S65743JHBS
  • UNII-S65743JHBS
  • DTXSID8041034
  • Gefitinib [USAN:INN:BAN]
  • MFCD04307832
  • D09XZB
  • Gefitinib (ZD1839)?
  • GEFITINIB [MART.]
  • Iressa|||ZD 1839
  • AC1L3X0A
  • GEFITINIB [WHO-DD]
  • SCHEMBL7866
  • XGALLCVXEZPNRQ-UHFFFAOYSA-N
  • Gefitinib,Iressa, ZD1839
  • Gefitinib,ZD-1839,Iressa
  • Gefitinib/ZD-1839,Iressa
  • DTXCID6021034
  • GEFITINIB [EMA EPAR]
  • KBioSS_002241
  • cc-596
  • CHEBI:49668
  • Gefitinib (JAN/USAN/INN)
  • MLS003899193
  • NSC-759856
  • Gefitinib - Bio-X trade mark
  • Gefitinib, Iressa, ZD1839
  • BDBM5447
  • cid_123631
  • EBD446
  • GTPL4941
  • orb1309499
  • SCHEMBL4535121
  • SCHEMBL4535128
  • SCHEMBL4535134
  • Gefitinib (JP18/USAN/INN)
  • GEFITINIB [ORANGE BOOK]
  • Tyrosine Kinase Inhibitor - Ns
  • ZD-1839, Iressa, Gefitinib
  • GEFITINIB [EP MONOGRAPH]
  • Gefitinib, >=98% (HPLC)
  • SCHEMBL29351046
  • SCHEMBL29351336
  • CTK7A0364
  • Gefitinib, 99% - 1MG 1mg
  • AOB6917
  • L01XE02
  • QCR-105
  • SYN1042
  • NSC715055
  • BCPP000221
  • GLXC-05820
  • HMS2089B19
  • HMS3244M21
  • HMS3244M22
  • HMS3244N21
  • HMS3295A21
  • HMS3413H08
  • HMS3654A07
  • HMS3677H08
  • HMS3714A05
  • HMS3748E17
  • HMS5079C05
  • Pharmakon1600-01502274
  • AMX10169
  • BCP01365
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
  • YWB97640
  • C22-H24-Cl-F-N4-O3
  • Tox21_111683
  • ABP000855
  • BBF-04570
  • CG0031
  • CID123631
  • EBC-07543
  • FC0028
  • Gefitinib for system suitability CRS
  • HY-50895G
  • HY-50895R
  • MSK159193
  • NCGC00159455-02
  • NSC759856
  • NSC800105
  • RS0033
  • s1025
  • STK621310
  • ZINC19632614
  • AKOS000280752
  • Tox21_111683_1
  • AB20814
  • AC-1556
  • ACN-032362
  • AN-5192
  • BCP9000718
  • CCG-220642
  • CID:123631
  • CS-0124
  • DB00317
  • FG10816
  • KS-1204
  • NSC 759856
  • NSC-715055
  • NSC-800105
  • SDCCGSBI-0634411.P005
  • KS-00000E11
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
  • NCGC00159455-03
  • NCGC00159455-04
  • NCGC00159455-05
  • NCGC00159455-06
  • NCGC00159455-08
  • NCGC00159455-09
  • NCGC00159455-14
  • 4CA-0562
  • AJ-74091
  • AK-72948
  • BC215794
  • BCB03_000781
  • BG164498
  • BR-72948
  • CJ-16232
  • EN002708
  • H018
  • HY-50895
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
  • SC-18023
  • SMR002204119
  • SY002154
  • 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
  • SID:376229605
  • AB0000095
  • LS-139916
  • ST2413546
  • A8219
  • AM20090619
  • CAS-184475-35-2
  • CS-0622782
  • FT-0602325
  • G0546
  • NS00006312
  • SW199108-4
  • EC-000.2409
  • J1.437.124I
  • A10422
  • CU-00000000396-1
  • D01977
  • EN300-123024
  • G-4408
  • J10250
  • K00240
  • N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
  • S-2176
  • 15215-EP2269994A1
  • 15215-EP2272827A1
  • 15215-EP2272832A1
  • 15215-EP2275413A1
  • 15215-EP2277865A1
  • 15215-EP2280006A1
  • 15215-EP2281813A1
  • 15215-EP2281815A1
  • 15215-EP2287156A1
  • 15215-EP2292234A1
  • 15215-EP2292615A1
  • 15215-EP2298768A1
  • 15215-EP2298778A1
  • 15215-EP2301533A1
  • 15215-EP2301933A1
  • 15215-EP2305640A2
  • 15215-EP2305671A1
  • 15215-EP2311807A1
  • 15215-EP2311827A1
  • 15215-EP2311840A1
  • 15215-EP2316832A1
  • 15215-EP2316833A1
  • 32333-EP2281815A1
  • 32333-EP2292615A1
  • 32333-EP2301933A1
  • 32333-EP2305640A2
  • 32333-EP2305671A1
  • 32333-EP2311827A1
  • AB01273954-01
  • AB01273954-02
  • AB01273954-03
  • AB01273954_04
  • 475G352
  • A812870
  • C419708
  • Q417824
  • SR-00000000262
  • I01-1227
  • SR-00000000262-2
  • SR-00000000262-3
  • BRD-K64052750-001-16-7
  • BRD-K64052750-001-17-5
  • BRD-K64052750-001-22-5
  • BRD-K64052750-001-23-3
  • Gefitinib, EuropePharmacopoeia (EP) Reference Standard
  • D000077156
  • Z1546610485
  • 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
  • 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-
  • N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
  • 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline
  • 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline
  • 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-
  • 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
  • 4-(3-chloro-4-fluoroanilino)-6-(3-morpholinopropoxy)-7-methoxyquinazoline
  • 857091-32-8
  • IRE
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(2,2,3,3,5,5,6,6-octadeuteriomorpholin-4-yl)propoxy]quinazolin-4-amine
  • 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline
  • 4-(3-CHLORO-4-FLUOROANILINO)-7-METHOXY-6-(3-MORPHOLINOPROPOXY)QUINAZOLINE
  • 4-Quinazolinamine,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
  • Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard
  • N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4 -ylpropoxy)quinazolin-4-amine
  • N-(3-Chloro-4-fluorophenyl)-6-(3-morpholinopropoxy)-7-methoxy-4-quinazolinamine
  • N-(3-Chloro-4-fluorophenyl)-6-(3-morpholinopropoxy)-7-methoxyquinazoline-4-amine
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholin) propoxy)-4-quinazolinamine
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(morpholin-4-yl)propoxy)quinazolin-4-amine
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-4-quinazolinamine
  • (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE
  • 1173976-40-3
  • 643-034-7
  • N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; hydrochloride
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine; 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; Gefitinib; Gefonib; Iressa; ZD 1839; ZD1839